Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Abstract

BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. OBJECTIVES: In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of …

Authors

Schwartz GG; Szarek M; Bittner VA; Diaz R; Goodman SG; Jukema JW; Landmesser U; López-Jaramillo P; Manvelian G; Pordy R

Journal

Journal of the American College of Cardiology, Vol. 78, No. 5, pp. 421–433

Publisher

Elsevier

Publication Date

August 2021

DOI

10.1016/j.jacc.2021.04.102

ISSN

0735-1097

Associated Experts

Gilmar Reis

Associate Professor (Part-Time), Faculty of Health Sciences

Visit profile

Labels